Author, as appears in the article.: Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
Department: Bioquímica i Biotecnologia
URV's Author/s: Folch Lopez, Jaume
Keywords: Tolcapone Pharmacokinetics Parkinson’s disease Parkinson's disease Opicapone Motor fluctuations Levodopa Improves Entacapone Dyskinesia Comt inhibitors Chemistry Catechol-o-methyltransferase Adjunct parkinson’s disease opicapone entacapone dyskinesia
Abstract: © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson’s disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. Areas covered: This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000–2019). Clinical and post-marketing data are also evaluated. Expert opinion: OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations.
Thematic Areas: Química Pharmacology & pharmacy Medicina ii Interdisciplinar Farmacia Engenharias iv Drug discovery Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciência da computação Astronomia / física
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 17460441
Author's mail: jaume.folch@urv.cat
Author identifier: 0000-0002-5051-8858
Record's date: 2023-02-19
Papper version: info:eu-repo/semantics/acceptedVersion
Link to the original source: https://www.tandfonline.com/doi/abs/10.1080/17460441.2020.1767580?journalCode=iedc20
Papper original source: Expert Opinion On Drug Discovery. 15 (9): 1-11
APA: Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A (2020). The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease. Expert Opinion On Drug Discovery, 15(9), 1-11. DOI: 10.1080/17460441.2020.1767580
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.1080/17460441.2020.1767580
Entity: Universitat Rovira i Virgili
Journal publication year: 2020
Publication Type: Journal Publications
Repositori URV